Case-Based Roundtable Meetings Spotlight June 2021: Hematologic Malignancies

Jonathon B. Cohen, MD, MS, moderated a Case-Based Roundtable event during which experts discussed treating patients with chronic lymphocytic leukemia during the COVID-19 pandemic.

David H. Vesole, MD, PhD, discussed the case of a 82-year old patient with transplant-ineligible multiple myeloma.

For patients who relapsed on their prior therapy and have triple-refractory multiple myeloma, selecting the best next-line of therapy is an important decision for their disease outcome. During a Targeted Oncology Case-Based Roundtable event, Peter Forsberg, MD, discussed this topic with a group.

During a Targeted Oncology Case-Based Roundtable events, Leo I. Gordon, MD, led a discussion about second-line treatment of diffuse large B-cell lymphoma.

During a Targeted Oncology Case-Based Roundtable event, Olalekan O. Oluwole, MD, MBBS, MPH, leads a discussion around identifying prognostic factors for a patients with transplant-eligible multiple myeloma.

Based on case details, Yi-Bin Chen, MD, and a group of peers discussed the probability of a patient developing acute graft-versus-host-disease and how to treat the disease.

Joseph Mikhael, MD, debated with a group pf peers about the impact of using frontline daratumumab on subsequent therapy.

Regarding the case of a 51-year-old man who first presented with pallor and worsening fatigue on exertion and was diagnosed with transplant-eligible multiple myeloma, Rafael Fonseca, MD, discussed available treatment options.

During a Targeted Oncology Case-Based Roundtable event, Jakub Svoboda, MD, discussed the case of a 75-year-old patient with diffuse large b-cell lymphoma.